PBMC were isolated from healthy controls and patients at baseline and after 3 (T3) or 6 months (T6) of treatment with NTZ. neurodegenerative disease from the central nervous system. It is generally accepted that migration of autoreactive T cells and monocytes across the blood-brain barrier (BBB) is of critical importance intended for the pathogenesis of the disease. Peroxisome Proliferator-Activated Receptors (PPAR) are transcription factors involved in metabolic and immune processes [1] and regulate To cell-mediated autoimmunity and severity of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS) [24]. In MS patients, peripheral blood mononuclear cells (PBMC) exhibit decreased PPARexpression inversely correlated with disease activity and PPARagonists may have beneficial effects [46]. Some studies have suggested that PPAR[2] and D5D-IN-326 PPAR/[7] specific agonists should also be considered as possible therapeutic strategies for this disorder. In the present exploratory study we D5D-IN-326 analyzed patients treated with Natalizumab (NTZ), a humanized monoclonal antibody against4 integrin molecules that inhibits transmigration of leukocytes to the CNS and induces complex alterations of immune functions in peripheral circulation [810]. However , the mechanisms underlying the beneficial effects and potential negative events of this treatment in MS are not fully comprehended. Based on the literature, we hypothesized that NTZ therapy could modify PPAR and CD36 gene expression in PBMC. CD36 is an innate immune receptor expressed in endothelial cells and microglia/macrophages upregulated by PPAR[1]. Blood levels of metalloproteinase-9 (MMP-9), neopterin, and osteopontin (OPN) were also measured, since their expression may be modulated by PPAR [1] and MS therapies [8, 11, 12]. == 2 . Material and Methods == == 2 . 1 . Patients == Twelve female patients, with relapsing-remitting MS (RRMS) and scheduled to start treatment with NTZ, were recruited from two MS clinical centers in Lisbon (Portugal). The mean age of these Rabbit Polyclonal to SSTR1 patients was 43 years (SD: 12); the mean duration of the disease 11. 6 years (SD: 8. 8); the mean expanded disability status scale is 4. 1 (SD: 1 . 9); and the annualized relapse rate is 2 . 9 (SD: 1 . 7). The mean annualized relapse price was calculated on the basis of the number of relapses occurring in each subject the previous two years under first-line immunomodulator treatment. Eleven patients received interferon beta-1a (Rebif, 44g s. c. ) 3 times weekly or interferon-1b (Betaferon, 250g h. c. ) every other day. 1 patient was medicated with glatiramer acetate injections. Blood samples were collected from these patients after a one-week washout period before starting treatment with 300 mg NTZ intravenously once month-to-month (baseline). At sampling, no patient was suffering from a relapse nor taking lipid-lowering agents and none had been treated with steroids for at least 1 month. Blood samples were also obtained at three and six months after switching therapy, just before the infusion of NTZ. During this study period, no patient suffered from a relapse or was medicated with corticosteroids. Almost all patients and nine age-matched female healthy controls signed an informed consent. The local Ethics Committee approved this study. == 2 . 2 . RNA Extraction and PCR Analysis == Blood was processed immediately after venipuncture and PBMC were collected by a lymphocyte separation medium gradient. Purification of mRNA was processed using QIAamp RNA Blood Mini Kit (Qiagen), according to the manufacturer’ protocol. PPAR, PPAR/, PPAR, and CD36 mRNA expression in PBMC was evaluated by quantitative RT-PCR. RNA was reverse-transcribed using random hexamer primers and Superscript reverse transcriptase (Life Technologies, France) and cDNAs were quantified either by Brilliant III Ultra-FastSYBRGreenusing specific oligonucleotides (for PPAR, CD36 and cyclophilin) or by Kit Brilliant Multiplex QPCR Master Mix Agilent to simultaneously detect the expression of PPAR, PPAR/, and cyclophilin on an Mx3000 apparatus (Stratagene, La Jolla, CA) (see Supplementary Information available online athttp://dx.doi.org/10.1155/2016/5716415for primers and probes used). The family member expression of each gene was calculated by the Ct method, where Ct is the value obtained by subtracting the Ct (threshold cycle) value of cyclophilin mRNA from the Ct value of the target gene. The amount of target relative to the cyclophilin mRNA was expressed because 2(Ct). == 2 . three or more. Biochemistry Assays == Plasma and serum were collected from the same samples and stored at 80C until use. Commercially available enzyme-linked D5D-IN-326 immunosorbent assays.